2-phenyl-5-trifluoromethyloxazole-4-carboxylic acid (6-[1,4]diazepan-1-yl-pyridin-3-yl)-amide | 1207829-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-phenyl-5-trifluoromethyloxazole-4-carboxylic acid (6-[1,4]diazepan-1-yl-pyridin-3-yl)-amide
• 英文别名: N-(6-(1,4-diazepan-1-yl)pyridin-3-yl)-2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamide；N-[6-(1,4-diazepan-1-yl)pyridin-3-yl]-2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carboxamide
• CAS: 1207829-56-8
• 化学式: C₂₁H₂₀F₃N₅O₂
• 分子量: 431.417
• InChiKey: NEVHMQIVHBQCEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  83.3
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-phenyl-5-trifluoromethyloxazole-4-carboxylic acid (6-[1,4]diazepan-1-yl-pyridin-3-yl)-amide 、 2-氟苯基异氰酸酯 生成 N-(6-(4-(2-fluorophenylcarbamoyl)-1,4-diazepan-1-yl)pyridin-3-yl)-2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamide
  参考文献：
  名称：

  INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

  摘要：

  本发明涉及一种新型杂环化合物作为二酰基甘油酰基转移酶（“DGAT”）抑制剂，包括所述杂环化合物的制药组合物以及使用所述化合物治疗或预防心血管疾病、代谢紊乱、肥胖或肥胖相关疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损。本发明的一种示例化合物如本摘要所示。

  公开号：

  US20110224193A1

文献信息

• Diacylglycerol Acyltransferase Inhibitors
  申请人：Bolin David Robert

  公开号：US20100035864A1

  公开（公告）日：2010-02-11

  Provided herein are compounds of the formula (1): as well as pharmaceutically acceptable salts thereof wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type 11 diabetes mellitus and metabolic syndrome.

  本文提供的化合物的化学式为(1)：以及其药用盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物可用于治疗疾病，例如肥胖症、2型糖尿病和代谢综合征。
• US8211884B2
  申请人：——

  公开号：US8211884B2

  公开（公告）日：2012-07-03
• [EN] INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE<br/>[FR] INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：SCHERING CORP

  公开号：WO2010059611A2

  公开（公告）日：2010-05-27

  The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ("DGAT") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: (We bring to your attention that the illustrative compound of the invention is not provided on this electronic version as it is provided in the abstract of the paper copy)